Skip to main content
Top
Published in: Endocrine 1/2015

01-02-2015 | Original Article

Uric acid induces oxidative stress via an activation of the renin–angiotensin system in 3T3-L1 adipocytes

Authors: Jun-xia Zhang, Yu-ping Zhang, Qi-nan Wu, Bing Chen

Published in: Endocrine | Issue 1/2015

Login to get access

Abstract

Hyperuricemia is recently reported involving in various obesity-related cardiovascular disorders, especially hypertension. However, the underlying mechanisms are not completely understood. In the present study, we investigated whether uric acid upregulates renin–angiotensin system (RAS) expression in adipocytes. We also examined whether RAS activation plays a role in uric acid-induced oxidative stress in adipocytes. The adipocytes of different phenotypes were incubated with uric acid for 48 h, respectively. Losartan (10−4 M) or captopril (10−4 M) was used to block adipose tissue RAS activation. mRNA expressions of angiotensinogen (AGT), angiotensin-converting enzyme-1 (ACE-1), renin, angiotensin type 1 receptor (AT1R), and angiotensin type 2 receptor (AT2R) were evaluated with real-time PCR. Angiotensin II concentrations in supernatant were measured by ELISA. Intracellular reactive species (ROS) levels were measured by fluorescent probe DCFH-DA, DHR, or NBT assay. The uric acid upregulated both RAS (AGT, ACE1, renin, AT1R, and AT2R) mRNA expressions and angiotensin II protein secretion and caused a significant increase in ROS production in 3T3-L1 adipocytes. These effects could be prevented by RAS inhibitors, either losartan or captopril. RAS activation has been causally implicated in oxidative stress induced by uric acid in 3T3-L1 adipocytes, suggesting a plausible mechanism through which hyperuricemia contributes to the pathogenesis of obesity-related cardiovascular diseases.
Literature
2.
go back to reference I. Saito, T. Saruta, K. Kondo, R. Nakamura, T. Oguro, K. Yamagami, Y. Ozawa, E. Kato, Serum uric acid and the renin–angiotensin system in hypertension. J. Am. Geriatr. Soc. 26, 241–247 (1978)PubMed I. Saito, T. Saruta, K. Kondo, R. Nakamura, T. Oguro, K. Yamagami, Y. Ozawa, E. Kato, Serum uric acid and the renin–angiotensin system in hypertension. J. Am. Geriatr. Soc. 26, 241–247 (1978)PubMed
3.
go back to reference D.I. Feig, B. Soletsky, R.J. Johnson, Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300, 924–932 (2008)CrossRefPubMedCentralPubMed D.I. Feig, B. Soletsky, R.J. Johnson, Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300, 924–932 (2008)CrossRefPubMedCentralPubMed
4.
go back to reference W. Susumu, K. Duk-Hee, F. Lili, N. Takahiko, K. John, L. Hui, Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40, 355–360 (2002)CrossRef W. Susumu, K. Duk-Hee, F. Lili, N. Takahiko, K. John, L. Hui, Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40, 355–360 (2002)CrossRef
5.
go back to reference M. Mazzali, J. Kanellis, L. Han, L. Feng, Y.Y. Xia, Q. Chen, Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. J. Physiol. Renal. Physiol. 282, F991–997 (2002)PubMed M. Mazzali, J. Kanellis, L. Han, L. Feng, Y.Y. Xia, Q. Chen, Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am. J. Physiol. Renal. Physiol. 282, F991–997 (2002)PubMed
6.
go back to reference D.B. Corry, P. Eslami, K. Yamamoto, M.D. Nyby, H. Makino, M.L. Tuck, Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J. Hypertens. 26, 269–275 (2008)CrossRefPubMed D.B. Corry, P. Eslami, K. Yamamoto, M.D. Nyby, H. Makino, M.L. Tuck, Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J. Hypertens. 26, 269–275 (2008)CrossRefPubMed
7.
go back to reference M.A. Yu, L.G. Sánchez-Lozada, R.J. Johnson, D.H. Kang, Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J. Hypertens. 28, 1234–1242 (2010)PubMed M.A. Yu, L.G. Sánchez-Lozada, R.J. Johnson, D.H. Kang, Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J. Hypertens. 28, 1234–1242 (2010)PubMed
8.
go back to reference G. Albertoni, E. Maquigussa, E. Pessoa, J.A. Barreto, F. Borges, N. Schor, Soluble uric acid increases intracellular calcium through an angiotensin II-dependent mechanism in immortalized human mesangial cells. Exp. Biol. Med. (Maywood) 235, 825–832 (2010)CrossRef G. Albertoni, E. Maquigussa, E. Pessoa, J.A. Barreto, F. Borges, N. Schor, Soluble uric acid increases intracellular calcium through an angiotensin II-dependent mechanism in immortalized human mesangial cells. Exp. Biol. Med. (Maywood) 235, 825–832 (2010)CrossRef
9.
go back to reference N.S. Kalupahana, N. Moustaid-Moussa, The renin–angiotensin system: a link between obesity, inflammation and insulin resistance. Obes. Rev. 13, 136–149 (2012)CrossRefPubMed N.S. Kalupahana, N. Moustaid-Moussa, The renin–angiotensin system: a link between obesity, inflammation and insulin resistance. Obes. Rev. 13, 136–149 (2012)CrossRefPubMed
10.
go back to reference S. Thatcher, F. Yiannikouris, M. Gupte, L. Cassis, The adipose renin–angiotensin system: role in cardiovascular disease. Mol. Cell. Endocrinol. 302, 111–117 (2009)CrossRefPubMedCentralPubMed S. Thatcher, F. Yiannikouris, M. Gupte, L. Cassis, The adipose renin–angiotensin system: role in cardiovascular disease. Mol. Cell. Endocrinol. 302, 111–117 (2009)CrossRefPubMedCentralPubMed
11.
go back to reference Y.Y. Sautin, T. Nakagawa, S. Zharikov, R.J. Johnson, Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am. J. Physiol. Cell Physiol. 293, C584–596 (2007)CrossRefPubMed Y.Y. Sautin, T. Nakagawa, S. Zharikov, R.J. Johnson, Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am. J. Physiol. Cell Physiol. 293, C584–596 (2007)CrossRefPubMed
12.
go back to reference A. Kurata, H. Nishizawa, S. Kihara, N. Maeda, M. Sonoda, T. Okada, K. Ohashi, T. Hibuse, K. Fujita, A. Yasui, A. Hiuge, M. Kumada, H. Kuriyama, I. Shimomura, T. Funahashi, Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 70, 1717–1724 (2006)CrossRefPubMed A. Kurata, H. Nishizawa, S. Kihara, N. Maeda, M. Sonoda, T. Okada, K. Ohashi, T. Hibuse, K. Fujita, A. Yasui, A. Hiuge, M. Kumada, H. Kuriyama, I. Shimomura, T. Funahashi, Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 70, 1717–1724 (2006)CrossRefPubMed
13.
go back to reference S.C. Frost, M.D. Lane, Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. J. Biol. Chem. 260, 2646–2652 (1985)PubMed S.C. Frost, M.D. Lane, Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. J. Biol. Chem. 260, 2646–2652 (1985)PubMed
14.
go back to reference M. Fujimoto, H. Masuzaki, T. Tanaka, S. Yasue, T. Tomita, K. Okazawa, An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 576, 492–497 (2004)CrossRefPubMed M. Fujimoto, H. Masuzaki, T. Tanaka, S. Yasue, T. Tomita, K. Okazawa, An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 576, 492–497 (2004)CrossRefPubMed
15.
go back to reference J. Kanellis, S. Watanabe, J.H. Li, D.H. Kang, P. Li, T. Nakagawa, Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41, 1287–1293 (2003)CrossRefPubMed J. Kanellis, S. Watanabe, J.H. Li, D.H. Kang, P. Li, T. Nakagawa, Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41, 1287–1293 (2003)CrossRefPubMed
16.
go back to reference K.K. Griendling, C.A. Minieri, J.D. Ollerenshaw, R.W. Alexander, Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74, 1141–1148 (1994)CrossRefPubMed K.K. Griendling, C.A. Minieri, J.D. Ollerenshaw, R.W. Alexander, Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74, 1141–1148 (1994)CrossRefPubMed
17.
go back to reference B.H. Jones, M.K. Standridge, J.W. Taylor, N. Moustaid, Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am. J. Physiol. 273, R236–242 (1997)PubMed B.H. Jones, M.K. Standridge, J.W. Taylor, N. Moustaid, Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am. J. Physiol. 273, R236–242 (1997)PubMed
18.
go back to reference C. Karlsson, K. Lindell, M. Ottosson, L. Sjostrom, B. Carlsson, L.M. Carlsson, Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J. Clin. Endocrinol. Metab. 83, 3925–3929 (1998)PubMed C. Karlsson, K. Lindell, M. Ottosson, L. Sjostrom, B. Carlsson, L.M. Carlsson, Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J. Clin. Endocrinol. Metab. 83, 3925–3929 (1998)PubMed
19.
go back to reference F. Massiéra, M. Bloch-Faure, D. Ceiler, K. Murakami, A. Fukamizu, J.M. Gasc, A. Quignard-Boulange, R. Negrel, G. Ailhaud, J. Seydoux, P. Meneton, M. Teboul, Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 15, 2727–2729 (2001)PubMed F. Massiéra, M. Bloch-Faure, D. Ceiler, K. Murakami, A. Fukamizu, J.M. Gasc, A. Quignard-Boulange, R. Negrel, G. Ailhaud, J. Seydoux, P. Meneton, M. Teboul, Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 15, 2727–2729 (2001)PubMed
20.
go back to reference S. Kim, M. Soltani-Bejnood, A. Quignard-Boulange, F. Massiera, M. Teboul, G. Ailhaud, J.H. Kim, N. Moustaid-Moussa, B.H. Voy, The adipose renin–angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin–angiotensin system. J. Biomed. Biotechnol. 2006, 27012 (2006)CrossRefPubMedCentralPubMed S. Kim, M. Soltani-Bejnood, A. Quignard-Boulange, F. Massiera, M. Teboul, G. Ailhaud, J.H. Kim, N. Moustaid-Moussa, B.H. Voy, The adipose renin–angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin–angiotensin system. J. Biomed. Biotechnol. 2006, 27012 (2006)CrossRefPubMedCentralPubMed
21.
go back to reference G.K. Glantzounis, E.C. Tsimoyiannis, A.M. Kappas, D.A. Galaris, Uric acid and oxidative stress. Curr. Pharm. Des. 11, 4145–4151 (2005)CrossRefPubMed G.K. Glantzounis, E.C. Tsimoyiannis, A.M. Kappas, D.A. Galaris, Uric acid and oxidative stress. Curr. Pharm. Des. 11, 4145–4151 (2005)CrossRefPubMed
22.
go back to reference R. Stocker, J. Keaney Jr, Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84, 1381–1478 (2004)CrossRefPubMed R. Stocker, J. Keaney Jr, Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84, 1381–1478 (2004)CrossRefPubMed
23.
go back to reference R.J. Johnson, D.H. Kang, D. Feig, S. Kivlighn, J. Kanellis, S. Watanabe, K.R. Tuttle, B. Rodriguez-Iturbe, J. Herrera-Acosta, M. Mazzali, Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41, 1183–1190 (2003)CrossRefPubMed R.J. Johnson, D.H. Kang, D. Feig, S. Kivlighn, J. Kanellis, S. Watanabe, K.R. Tuttle, B. Rodriguez-Iturbe, J. Herrera-Acosta, M. Mazzali, Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41, 1183–1190 (2003)CrossRefPubMed
24.
go back to reference E. Bonora, G. Targher, M.B. Zenere, F. Saggiani, V. Cacciatori, F. Tosi, D. Travia, M.G. Zenti, P. Branzi, L. Santi, M. Muggeo, Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The verona young men atherosclerosis risk factors study. Int. J. Obes. Relat. Metab. Disord. 20, 975–980 (1996)PubMed E. Bonora, G. Targher, M.B. Zenere, F. Saggiani, V. Cacciatori, F. Tosi, D. Travia, M.G. Zenti, P. Branzi, L. Santi, M. Muggeo, Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The verona young men atherosclerosis risk factors study. Int. J. Obes. Relat. Metab. Disord. 20, 975–980 (1996)PubMed
25.
go back to reference T. Ogura, K. Matsuura, Y. Matsumoto, Y. Mimura, M. Kishida, F. Otsuka, K. Tobe, Recent trends of hyperuricemia and obesity in Japanese male adolescents, 1991 through 2002. Metabolism 53, 448–453 (2004)CrossRefPubMed T. Ogura, K. Matsuura, Y. Matsumoto, Y. Mimura, M. Kishida, F. Otsuka, K. Tobe, Recent trends of hyperuricemia and obesity in Japanese male adolescents, 1991 through 2002. Metabolism 53, 448–453 (2004)CrossRefPubMed
26.
go back to reference S. Muraoka, T. Miura, Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol. Toxicol. 93, 284–289 (2003)CrossRefPubMed S. Muraoka, T. Miura, Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol. Toxicol. 93, 284–289 (2003)CrossRefPubMed
27.
go back to reference M. Mazzali, J. Hughes, Y.G. Kim, J.A. Jefferson, D.H. Kang, K.L. Gordon, H.Y. Lan, S. Kivlighn, R.J. Johnson, Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38, 1101–1106 (2001)CrossRefPubMed M. Mazzali, J. Hughes, Y.G. Kim, J.A. Jefferson, D.H. Kang, K.L. Gordon, H.Y. Lan, S. Kivlighn, R.J. Johnson, Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38, 1101–1106 (2001)CrossRefPubMed
28.
go back to reference L.G. Sánchez-Lozada, V. Soto, E. Tapia, C. Avila-Casado, Y.Y. Sautin, T. Nakagawa, M. Franco, B. Rodríguez-Iturbe, R.J. Johnson, Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am. J. Physiol. Renal. Physiol. 295, F1134–1141 (2008)CrossRefPubMedCentralPubMed L.G. Sánchez-Lozada, V. Soto, E. Tapia, C. Avila-Casado, Y.Y. Sautin, T. Nakagawa, M. Franco, B. Rodríguez-Iturbe, R.J. Johnson, Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am. J. Physiol. Renal. Physiol. 295, F1134–1141 (2008)CrossRefPubMedCentralPubMed
29.
go back to reference R.M. Touyz, X. Chen, F. Tabet, G. Yao, G. He, M.T. Quinn, P.J. Pagano, E.L. Schiffrin, Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 90, 1205–1213 (2002)CrossRefPubMed R.M. Touyz, X. Chen, F. Tabet, G. Yao, G. He, M.T. Quinn, P.J. Pagano, E.L. Schiffrin, Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ. Res. 90, 1205–1213 (2002)CrossRefPubMed
30.
go back to reference R.J. Johnson, D.I. Feig, J. Herrera-Acosta, D.H. Kang, Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 45, 18–20 (2005)CrossRefPubMed R.J. Johnson, D.I. Feig, J. Herrera-Acosta, D.H. Kang, Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 45, 18–20 (2005)CrossRefPubMed
31.
go back to reference K. Masuo, H. Kawaguchi, H. Mikami, T. Ogihara, M.L. Tuck, Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42, 474–480 (2003)CrossRefPubMed K. Masuo, H. Kawaguchi, H. Mikami, T. Ogihara, M.L. Tuck, Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42, 474–480 (2003)CrossRefPubMed
32.
go back to reference S. Furukawa, T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, Y. Nakajima, O. Nakayama, M. Makishima, M. Matsuda, I. Shimomura, Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114, 1752–1761 (2004)CrossRefPubMedCentralPubMed S. Furukawa, T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, Y. Nakajima, O. Nakayama, M. Makishima, M. Matsuda, I. Shimomura, Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114, 1752–1761 (2004)CrossRefPubMedCentralPubMed
Metadata
Title
Uric acid induces oxidative stress via an activation of the renin–angiotensin system in 3T3-L1 adipocytes
Authors
Jun-xia Zhang
Yu-ping Zhang
Qi-nan Wu
Bing Chen
Publication date
01-02-2015
Publisher
Springer US
Published in
Endocrine / Issue 1/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0239-5

Other articles of this Issue 1/2015

Endocrine 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.